Niva Bupa Health Insurance Company Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here

Click and Sign Up to Get Live Updates on Q3 Results 

Niva Bupa Health Insurance Company Q3 results for FY26 are scheduled to be announced on 29th January 2026. Financial analysts anticipate an increase in revenue due to higher sales and a significant rise in PAT.

Niva Bupa Health Insurance CompanyQ3 Results 2026 Preview

• Niva Bupa Health Insurance Company’s revenue is expected to be in the range of ₹1,203.71 crore, a 6.06% YoY decrease. 
• Profit After Tax, or PAT, is projected to rise by 1.69% YoY. 
• Niva Bupa Health Insurance Company. EBITDA is expected to rise to ₹2.63 crore. 
• Net profit is ₹13.24 crore, a rise 1.69% YoY.

Niva Bupa Health Insurance Company Share Performance 

• Over the past six months, ITC’s share price has fallen by 6.99% to ₹77.15.
• Moreover, over the past year, the stock has increased by 1.07%.
• Despite this weak short-term performance, ITC’s stock has delivered a financially sound 356.86% return over the past 5 years.
• As of 28th January 2026, the stock traded at ₹77.15 per share.

Key Factors to Watch for Niva Bupa Health Insurance Company Q3 Results FY26 

• Investment Portfolio Performance: Niva Bupa Health Insurance Company’s performance is deeply tied to the value of its holdings rather than standalone operating sales volumes.
•  Sales & Cash Flow Drivers (Dividend, Interest, Pledge Fees):  Tracking trends in these inflows — especially how much dividends and interest contribute quarter to quarter — gives insight into the sustainability of reported revenue.
• Profitability & margins: EBITDA and PAT trends reflecting operational efficiency and product mix changes.
• Backward integration & cost efficiencies: Progress on diversifying capacity expansions to reduce import dependence and costs.
• Retail expansion & channel reach: Growth of retail outlets and direct management engagement supporting long‑term demand visibility.
  

Final Thoughts

Niva Bupa Health Insurance Company will announce its Q3 FY26 results on 29th January 2026. Analysts expect 38.10% YoY revenue growth, a 15.60% fall in PAT, and a 20.90% fall in EBITDA. Niva Bupa is one of India’s fastest-growing standalone health insurers, showing strong premium and profit growth with increasing retail presence — making it a compelling structural growth play in a still under-penetrated Indian health insurance market.

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!

Recent Articles

Top 10 Penny Stocks in India | Penny Stocks to Buy in 2026

Best Stocks to Buy Today: Explore Best Stocks With Expected Trends

Milky Mist Dairy Foods IPO Details: Everything You Should Know about 

Karbonsteel Engineering IPO GMP & Review: Should You Apply or Avoid?

Taurian MPS IPO GMP & Review: Should You Apply or Avoid?

Shringar House of Mangalsutra IPO GMP & Review: Apply or Avoid?

Dev ITCelerator IPO GMP & Review: Apply or Avoid?

Krupalu Metals IPO GMP: Day 3 IPO Live Updates